Target Name: FAT3
NCBI ID: G120114
Other Name(s): Protocadherin Fat 3 (isoform 2) | CDHR10 | hFat3 | FAT atypical cadherin 3 | FAT3 variant 2 | FAT tumor suppressor homolog 3 | CDHF15 | cadherin-related family member 10 | FAT3_HUMAN | Cadherin family member 15 | FAT atypical cadherin 3, transcript variant 2 | Protocadherin Fat 3 | Cadherin-related family member 10 | cadherin family member 15 | KIAA1989

FAT3: A Drug Target / Disease Biomarker

FAT3, also known as fatty acid amide hydrolase (FAAH), is a protein that is expressed in various tissues throughout the body. It is involved in the breakdown of fatty acids, which are essential for the body's energy metabolism. FAT3 is a key enzyme in the triglyceride metabolism, which is the process by which dietary fat is broken down into fatty acids and added to the bloodstream for energy production.

Recent studies have suggested that FAT3 may have potential as a drug target or biomarker. First, researchers have found that inhibiting FAT3 activity can lead to a decrease in the levels of fatty acids in the bloodstream, which could make it an effective way to treat conditions that involve fatty acid imbalances, such as obesity, type 2 diabetes, and cardiovascular disease.

Additionally, FAT3 has been shown to be involved in the regulation of cellular signaling pathways that are important for various biological processes, including metabolism, inflammation, and stress response. This suggests that FAT3 may be a useful biomarker for diseases that involve disruptions in these pathways, such as cancer, autoimmune diseases, and neurodegenerative disorders.

FAT3 is also a potential drug target for treating various psychiatric and neurological disorders. Studies have shown that FAT3 is involved in the synthesis and storage of certain neurotransmitters, such as dopamine and serotonin, which are involved in mood, emotion, and other cognitive processes. Therefore, inhibiting FAT3 activity could be a promising approach to treating disorders that involve disruptions in these processes, such as depression, anxiety, and schizophrenia.

In addition to its potential therapeutic applications, FAT3 is also a valuable research tool for studying the biology of fatty acid metabolism. The FAT3 gene has been extensively studied, and researchers have identified various mechanisms by which FAT3 activity is regulated. For example, some studies have shown that FAT3 activity can be regulated by factors such as diet, physical activity, and environmental factors such as temperature and humidity.

Overall, FAT3 is a protein that has significant potential as a drug target or biomarker. Its involvement in the regulation of fatty acid metabolism and its involvement in various signaling pathways make it an attractive target for the development of new treatments for a variety of disorders. Further research is needed to fully understand the biology of FAT3 and its potential therapeutic applications.

Protein Name: FAT Atypical Cadherin 3

Functions: May play a role in the interactions between neurites derived from specific subsets of neurons during development

More Common Targets

FAT4 | FATE1 | Fatty Acid Binding Protein | Fatty acid desaturase | FAU | FAUP1 | FAUP4 | FAXC | FAXDC2 | FBF1 | FBH1 | FBL | FBLIM1 | FBLL1 | FBLN1 | FBLN2 | FBLN5 | FBLN7 | FBN1 | FBN2 | FBN3 | FBP1 | FBP2 | FBRS | FBRSL1 | FBXL12 | FBXL13 | FBXL14 | FBXL15 | FBXL16 | FBXL17 | FBXL18 | FBXL19 | FBXL19-AS1 | FBXL2 | FBXL20 | FBXL21P | FBXL22 | FBXL3 | FBXL4 | FBXL5 | FBXL6 | FBXL7 | FBXL8 | FBXL9P | FBXO10 | FBXO11 | FBXO15 | FBXO16 | FBXO17 | FBXO2 | FBXO21 | FBXO22 | FBXO24 | FBXO25 | FBXO27 | FBXO28 | FBXO3 | FBXO30 | FBXO31 | FBXO32 | FBXO33 | FBXO34 | FBXO36 | FBXO38 | FBXO39 | FBXO4 | FBXO40 | FBXO41 | FBXO42 | FBXO43 | FBXO44 | FBXO45 | FBXO46 | FBXO47 | FBXO48 | FBXO5 | FBXO6 | FBXO7 | FBXO8 | FBXO9 | FBXW10 | FBXW10B | FBXW11 | FBXW12 | FBXW2 | FBXW4 | FBXW4P1 | FBXW5 | FBXW7 | FBXW7-AS1 | FBXW8 | FBXW9 | Fc-gamma Receptor (FCGR) | FCAMR | FCAR | FCER1A | FCER1G | FCER2 | FCF1